Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Vaccine
- Publicado em
- 10 jan 2025
- Citações
- 3
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®
Sharon E Frey, Rebecca Brady, Lisa Jackson, Paul Goepfert, Hana M El Sahly, Robert L Atmar, Richard Rupp, C Buddy Creech, Getahun Abate, Grant Paulsen et al.
Descritores MeSH
- Influenza A Virus, H7N9 Subtype
- Influenza Vaccines
- Polysorbates
- Squalene
- Adjuvants, Immunologic
- Influenza, Human
- Immunogenicity, Vaccine
- Female
- Antibodies, Viral
- Adult
Veja também
Estudos relacionados
- A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults
- Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults
- Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial
- Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial